A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Watch
Minimal Residual Disease Testing’s Variability Across Cancer Types
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.
What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar
An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.
Delving Into Clinical Research For Patients With Breast Cancer
Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.
Clinical Trials to Watch in Triple-Negative Breast Cancer
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
Understanding Biliary Tract Cancer and The Current Standard of Care
An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.
What Patients With Cancer Should Know About DPD Deficiency Prior to Chemo
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.
GAP Triplet May Be Less Safe Than Doublet Chemo in Biliary Tract Cancer
An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.
COSMIC-313 Trial Lead Breaks Down Treatment Intensification in RCC
Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
Personalized Medicine Makes Strides Across the GU Oncology Treatment Space
Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.
The Importance of Genetic Testing in Metastatic Colorectal Cancer
An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.
Personalized Cancer Vaccine Demonstrates Responses in Kidney Cancer
Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
Explaining PROs From the TiNivo-2 Study in Advanced Renal Cell Carcinoma
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Treatment Intensification Adoption Differences Across Prostate Cancer
There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.
An Expert Explains Updated Data For Patients With GU Cancers
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.
Breaking Down the Implications of Calquence Combination Therapy in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.
Empowering Patients and Advocating For Yourself After Cervical Cancer
Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.
An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
Breaking Down The Importance of Targeted Therapies in Colorectal Cancer Care
Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.
Explaining KRAS Mutations For Patients With Colorectal Cancer
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Personalized Kidney Cancer Vaccine May Help Prevent Future Relapse
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
The Importance of Utilizing Support Networks Following a Cancer Diagnosis
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
An Expert Breaks Down What DPD Is and Labeling Updates From The FDA
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
Impact of PV on Lifestyle
A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes patients can make, available support resources and educational materials while offering guidance for living with the condition.
Circulating Tumor DNA May Have Prognostic Value in Kidney Cancer
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.
